Research Topics
| J A CohenSummaryAffiliation: Cleveland Clinic Foundation Country: USA Publications
| Collaborators
|
Detail Information
Publications
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialJeffrey A Cohen
Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
Lancet 380:1819-28. 2012..We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial...- Disability outcome measures in multiple sclerosis clinical trials: current status and future prospectsJeffrey A Cohen
Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Lancet Neurol 11:467-76. 2012..A collaborative approach that involves academic experts, regulators, industry representitives, and funding agencies is needed to most effectively develop disability outcome measures... 
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MSJ A Cohen
Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Neurology 68:939-44. 2007..To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple sclerosis...- The future of multiple sclerosis treatmentJeffrey A Cohen
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA
J Neurol Sci 277:S55-61. 2009..The place that these therapies will come to occupy in future years will depend on their relative benefits and risks... - Results of the Avonex Combination Trial (ACT) in relapsing-remitting MSJ A Cohen
Mellen Center U 10, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Neurology 72:535-41. 2009..v. methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNbeta-1a monotherapy... - Emerging therapies for relapsing multiple sclerosisJeffrey A Cohen
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA
Arch Neurol 66:821-8. 2009..A sizable number of new agents are under investigation currently. This article reviews emerging agents that have shown promise in phase 2 trials... - Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline dataJ A Cohen
Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Mult Scler 14:370-82. 2008.... - Oral fingolimod or intramuscular interferon for relapsing multiple sclerosisJeffrey A Cohen
Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
N Engl J Med 362:402-15. 2010..Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis... - Benefit of interferon beta-1a on MSFC progression in secondary progressive MSJ A Cohen
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
Neurology 59:679-87. 2002..Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS... - Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosisJeffrey A Cohen
Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Ann Neurol 69:759-77. 2011..5 to 10x the approved 0.5 mg dose. Fingolimod's unique mechanism of action distinguishes it from all other currently approved MS therapies... - Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trialJ A Cohen
The Mellen Center U10, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
Arch Neurol 58:961-7. 2001..The MSFC is the primary outcome measure in the ongoing multinational phase 3 trial of interferon beta-1a (Avonex) in patients with secondary progressive MS... - Assessing disability progression with the Multiple Sclerosis Functional CompositeR A Rudick
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA
Mult Scler 15:984-97. 2009..However, the clinical meaning of an MSFC Z-score change is not obvious. This study instead used MSFC component data to define a patient-specific disease progression event... - Therapy of relapsing multiple sclerosis. Treatment approaches for nonrespondersJ A Cohen
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
J Neuroimmunol 98:29-36. 1999..Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary... - A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon betaD R Smith
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
Mult Scler 11:573-82. 2005..75; P =0.011). CY/MP treatment was well tolerated. CONCLUSION: Combination therapy with CY/MP and IFNbeta-Ia decreased the number of Gd+ lesions and slowed clinical activity in patients with previously active disease on IFNbeta alone... - Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT studyD M Miller
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
Mult Scler 12:180-6. 2006..The IMPACT data permit a detailed assessment of the relation between clinical and self-reported measures... - Multiple sclerosis: the importance of early recognition and treatmentR J Fox
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
Cleve Clin J Med 68:157-71. 2001..Several lines of evidence demonstrate that tissue damage occurs very early in the disease, and much of this damage is clinically silent... - Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman
Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
Neurology 71:1134-41. 2008..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)... - Contrast letter acuity as a visual component for the Multiple Sclerosis Functional CompositeL J Balcer
Division of Neuro ophthalmology, Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
Neurology 61:1367-73. 2003..Visual dysfunction is one of the most common causes of disability in multiple sclerosis (MS). The Multiple Sclerosis Functional Composite (MSFC), a new clinical trial outcome measure, does not currently include a test of visual function... - Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosisB A C Cree
Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
Neurology 63:2039-45. 2004..African American (AA) individuals are thought to develop multiple sclerosis (MS) less frequently than Caucasian American (CA) individuals... - Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosisM L Baier
Center for Research Methodology and Biometrics, Cooper Institute, 14023 Denver West Parkway, 100, Golden, CO 80401, USA
Neurology 64:992-5. 2005..To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis Functional Composite (MSFC)... - Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging studyA D Goodman
Department of Neurology, University of Rochester, Rochester, NY 14642, USA rmc rochester edu
Mult Scler 13:357-68. 2007..To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg twice daily... - Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effectsH L Weiner
Multiple Sclerosis Center, Brigham and Women s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston 02115, USA
Mult Scler 8:142-54. 2002..Cyclophosphamide is currently used in patients whose disease is not controlled by beta-interferon or glatiramer acetate and those with rapidly worsening MS... - Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessmentC H Polman
Department of Neurology, Free University Medical Center in Amsterdam, PO Box 4075, 1007 MB Amsterdam, The Netherlands
Neurology 70:1134-40. 2008..Guidance is also provided on the ethics of alternative trial designs and the balance between study subject burden and risk, scientific rationale and interpretability of trial outcomes...